Entering text into the input field will update the search result below

Taysha shares pre-clinical data for gene therapy in epilepsy due to SLCA13A5 deficiency

Dec. 06, 2021 4:47 PM ETTaysha Gene Therapies, Inc. (TSHA)By: Dulan Lokuwithana, SA News Editor
  • Disclosing a late-breaking abstract and poster presentation conducted at a medical event, Taysha Gene Therapies (NASDAQ:TSHA) says it expects to seek regulatory clearances to start clinical trials for its experimental gene therapy TSHA-105 in patients with SLC13A5-related epilepsy.
  • SLC13A5-related epilepsy

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.